



UroGen Pharma to Present at Upcoming Investor Conferences

January 30, 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Jan. 30, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate at the following investor conferences in February:

Guggenheim Securities SMID Cap Biotech Conference

Date / Time: February 5, 2025 at 10:30 AM ET
Format: Presentation and 1x1 investor meetings
Location: New York, NY
Webcast Link: [here](#)

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Date / Time: February 11, 2025 at 1:20 PM ET
Format: Presentation and 1x1 investor meetings
Location: Virtual
Webcast Link: [here](#)

Webcasts from the conferences will also be available on UroGen's Investor Relations [website](#). A replay will be available on the site for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed *RTGel*® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250130241788/en/): <https://www.businesswire.com/news/home/20250130241788/en/>

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.